Premium
Small Scale Preparation and Clinical Use of Factor IX‐Prothrombin Complex
Author(s) -
Barrowcliffe T. W.,
Stableforth Penelope,
Dormandy Katharine M.
Publication year - 1973
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1973.tb03534.x
Subject(s) - prothrombin complex , factor ix , prothrombin complex concentrate , chemistry , chromatography , yield (engineering) , dialysis , medicine , factor vii , nuclear chemistry , gastroenterology , surgery , coagulation , materials science , warfarin , metallurgy , atrial fibrillation
. A. procedure is described for the preparation of a concentrate of factors II, VII, IX and X, using a modification of the method of Bruning and Loelioer, involving aluminium hydroxide adsorption of ACD plasma followed by phosphate elution and dialysis. The concentrate produced had an average factor IX activity of 7.4 U/ml with a yield of 61% and a purification of 34.5. Clinical trials in patients with either a congenital deficiency of factor IX or liver disease showed that the concentrate was well tolerated and was an effective haemostatic agent. The average factor IX response was 1.09% for each U/kg injected, giving a recovery of 48%.